Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, with an increasing incidence. Pemafibrate is a novel selective peroxisome proliferator-activated receptor-a (PPAR-a) modulator which is expected to improve NAFLD. The aim of this study is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinozaki, Satoshi, Tahara, Toshiyuki, Miura, Kouichi, Lefor, Alan Kawarai, Yamamoto, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850303/
https://www.ncbi.nlm.nih.gov/pubmed/36683866
http://dx.doi.org/10.5114/ceh.2022.120099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850303/
https://www.ncbi.nlm.nih.gov/pubmed/36683866
http://dx.doi.org/10.5114/ceh.2022.120099

Ejemplares similares